NSPR InspireMD

Filed: 27 May 21, 8:00am






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 27, 2021


InspireMD, Inc.

(Exact name of registrant as specified in its charter)


Delaware 001-35731 26-2123838

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


4 Menorat Hamaor St.

Tel Aviv, Israel

(Address of principal executive offices) (Zip Code)


(888) 776-6804

(Registrant’s telephone number, including area code)



(Former Name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) 

Name of exchange on

which registered

Common Stock, par value $0.0001 per share NSPR The Nasdaq Capital Market LLC

Series A Warrants, exercisable for one share of Common Stock

 NSPR.WS NYSE American

Series B Warrants, exercisable for one share of Common Stock



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]







Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing


On May 27, 2021, InspireMD, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, determined to voluntarily withdraw the listing of its Series A and Series B warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Warrants”), from the New York Stock Exchange (“NYSE”) and transfer the listing of the Warrants to the Nasdaq Capital Market (“Nasdaq”). The Company expects to voluntarily delist the Warrants from the NYSE effective as of the close of trading on June 7, 2021, and that trading of the Warrants will commence on Nasdaq at market open on June 8, 2021.


The Warrants have been approved for listing on Nasdaq, where each of the Warrants will continue to trade under the stock symbols “NSPRW,” and “NSPRZ,” respectively.


Item 7.01. Regulation FD Disclosure.


The Company issued the press release attached hereto as Exhibit 99.1 in connection with the transfer of the listing of the Warrants to Nasdaq.


The information included in this Current Report under Item 7.01, including Exhibit 99.1, is deemed to be “furnished” and shall not be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act or the Exchange Act.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit Number Description
99.1 Press release dated May 27, 2021







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 InspireMD, Inc.
Date: May 27, 2021By:/s/ Craig Shore
 Name:Craig Shore
 Title:Chief Financial Officer